Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific (TMO) is a global leader in laboratory instruments, consumables, and services that support scientific research, healthcare, and industrial applications. With a diversified portfolio across life‑sciences research tools, analytical instruments, specialty diagnostics and laboratory services, the company benefits from recurring consumables and service revenue as well as long‑term demand driven by R&D, healthcare spending and public health needs. Its scale and distribution reach help it serve pharmaceutical, biotech, academic and clinical customers worldwide. Investors should note strengths such as a broad product mix, exposure to steady R&D trends and potential margin resilience from high‑margin consumables, but also risks including integration of acquisitions, regulatory scrutiny, and sensitivity to capital spending cycles. Market cap and valuation can fluctuate; this summary is educational and not personal investment advice. Consider how the company fits your risk profile and investment horizon before making decisions.
Why It's Moving
Thermo Fisher signals confidence with $5B share buyback amid insider option exercises.
Thermo Fisher Scientific authorized a massive $5 billion share repurchase program, underscoring management's belief in the company's undervalued stock and robust future growth in life sciences. Recent insider transactions by EVP & COO Michel Lagarde, involving option exercises and sales, reflect routine profit-taking while the stock edges higher near 52-week highs.
- Board approved $5B open-market buyback with no expiration, allowing repurchase of ~2.4% of shares as a vote of confidence in ongoing momentum[2][3][7].
- EVP & COO Michel Lagarde exercised over 104,000 options at $105.17/share on Dec 4-5, selling portions at ~$580-584 to capture gains from the rally[1][5].
- Stock up ~3% in past month and 18% over three months, trading below analyst targets amid strength in genomics tools and precision medicine demand[4].
Thermo Fisher signals confidence with $5B share buyback amid insider option exercises.
Thermo Fisher Scientific authorized a massive $5 billion share repurchase program, underscoring management's belief in the company's undervalued stock and robust future growth in life sciences. Recent insider transactions by EVP & COO Michel Lagarde, involving option exercises and sales, reflect routine profit-taking while the stock edges higher near 52-week highs.
- Board approved $5B open-market buyback with no expiration, allowing repurchase of ~2.4% of shares as a vote of confidence in ongoing momentum[2][3][7].
- EVP & COO Michel Lagarde exercised over 104,000 options at $105.17/share on Dec 4-5, selling portions at ~$580-584 to capture gains from the rally[1][5].
- Stock up ~3% in past month and 18% over three months, trading below analyst targets amid strength in genomics tools and precision medicine demand[4].
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Thermo Fisher's stock, as its target price indicates potential growth.
Financial Health
Thermo Fisher is performing well with strong revenue and cash flow, despite some cost challenges.
Dividend
Thermo Fisher's low dividend yield of 0.29% means it offers minimal returns in dividends. If you invested $1000 you would be paid $2.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TMO
Activist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: August 11, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketEmpire Builders
These companies are led by visionaries who excel at growing through smart acquisitions. Our analysts have carefully selected businesses with proven ability to buy competitors, integrate them successfully, and build lasting market power.
Published: June 17, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Consumables Revenue
Consumables and reagents can create predictable revenue and support margins, though demand can vary with research funding and market cycles.
Global Scientific Reach
A broad international footprint serves diverse customers from pharma to academia, offering resilience but also exposure to regional regulation and economic shifts.
Innovation and Scale
Product innovation and acquisitions expand the addressable market, yet integration and execution risks can affect near‑term results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
